Clinical characteristics and etiology-specific outcome in pediatric hypertrophic cardiomyopathy
Felix Minette(Heidelberg University), Christoph P. Hofmann(Heidelberg University), Angela Merzweiler(Heidelberg University), Sebastian Burkart(Heidelberg University), Norbert Frey(Heidelberg University), Matthias Gorenflo(Heidelberg University), Maja Hempel(Helmholtz Zentrum München), Alexander Kovacevic(Heidelberg University), Maximilian Klass(Heidelberg University), Mirko Völkers(Heidelberg University)
Cited by 2
Related Papers
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2020|1.2k
Left Ventricular Unloading Is Associated With Lower Mortality in Patients With Cardiogenic Shock Treated With Venoarterial Extracorporeal Membrane Oxygenation
|Circulation|2020|502
ATF6 Decreases Myocardial Ischemia/Reperfusion Damage and Links ER Stress and Oxidative Stress Signaling Pathways in the Heart
|Circulation Research|2016|329
RIP3, a kinase promoting necroptotic cell death, mediates adverse remodelling after myocardial infarction
|Cardiovascular Research|2014|316
Myocardial AKT: The Omnipresent Nexus
|Physiological Reviews|2011|222